Wantstats
Company ProfilePremium

Ardelyx, Inc.

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
Ardelyx, Inc. - Healthcare showcase

Year Founded & Workforce

2007

75 Employees

Industry

Healthcare

Services

Pipeline for IBS-C
A

Ardelyx, Inc. Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Ardelyx, Inc. Overview

Company Headquarter: Delaware, US

Founded: 2007

Workforce: 75 Employees

Company Working:

Ardelyx, Inc. is a specialized biopharmaceutical company. It manufactures and sells disruptive medicines for the treatment of cardiorenal and gastrointestinal diseases. The lead product of the company is tenapanor, which has completed the Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as the Phase III clinical trial for the treatment of hyperphosphatemia.

Strategy

To develop therapeutics for cardiorenal and gastrointestinal diseasesThe company is involved in research and development for developing new treatments for gastrointestinal and cardiorenal diseases

Company Snapshot

$24M

Revenue

75

Employees

2007

Founded

SWOT Analysis

Strengths

  • Well-established product portfolio

Weaknesses

  • Limited presence in developing economies
  • Resolving liquidities of the company

Opportunities

  • Business expansion in the healthcare segment through investments in mergers and acquisitions

Threats

  • Fluctuating exchange rates
  • Government regulations for product approvals

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
–Clinical TrialsThe company submitted a new drug application to the US Food and Drug Administration of Tenapanor for IBS-C.
–AgreementThe company entered into a license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited (Fosun Pharma) providing Fosun Pharma with exclusive rights to develop and commercialize tenapanor in China for the treatment of patients with hyperphosphatemia related to chronic kidney disease, as well as patients with IBS-C.
–AgreementThe company entered into a license agreement with Kyowa Hakko Kirin Co., Ltd. for the development and commercialization of tenapanor in Japan.

Product Offering

  • Ardelyx, Inc.
    • Pipeline for IBS-C

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales rose from USD 24 Mn in 2015 to USD 42 Mn in 2017.
Ardelyx, Inc. — By Business Segment
Series (USD Mn)201520162017
Sales24—42
R&D Expenditure39.8075.5

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →